Cargando…

Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI)

At the 2018 Gastrointestinal Cancer Symposium, sponsored by the American Society of Clinical Oncology, significant advances in the management of hepatocellular carcinoma (HCC) were announced. In intermediate-stage disease (Barcelona Clinic Liver Cancer stage B), interest in combining transarterial c...

Descripción completa

Detalles Bibliográficos
Autores principales: de Jesus, Victor Hugo Fonseca, Dettino, Aldo Lourenço Abbade
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174912/
https://www.ncbi.nlm.nih.gov/pubmed/30324097
http://dx.doi.org/10.2147/JHC.S171396
_version_ 1783361385691873280
author de Jesus, Victor Hugo Fonseca
Dettino, Aldo Lourenço Abbade
author_facet de Jesus, Victor Hugo Fonseca
Dettino, Aldo Lourenço Abbade
author_sort de Jesus, Victor Hugo Fonseca
collection PubMed
description At the 2018 Gastrointestinal Cancer Symposium, sponsored by the American Society of Clinical Oncology, significant advances in the management of hepatocellular carcinoma (HCC) were announced. In intermediate-stage disease (Barcelona Clinic Liver Cancer stage B), interest in combining transarterial chemoembolization and sorafenib has been reignited as a consequence of the TACTICS trial. In advanced-stage disease (BCLC C), external-beam radiotherapy combined with transarterial chemoembolization proved to be superior to sorafenib in patients with portal vein thrombosis according to the START trial. Also, in patients with advanced-stage HCC, the CELESTIAL trial demonstrated survival benefits for patients undergoing treatment with cabozantinib in the second-line setting. Lastly, recent data on the activity of pembrolizumab in patients with HCC highlight the role of immunotherapy in the management of this disease in the years to come.
format Online
Article
Text
id pubmed-6174912
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61749122018-10-15 Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI) de Jesus, Victor Hugo Fonseca Dettino, Aldo Lourenço Abbade J Hepatocell Carcinoma Review At the 2018 Gastrointestinal Cancer Symposium, sponsored by the American Society of Clinical Oncology, significant advances in the management of hepatocellular carcinoma (HCC) were announced. In intermediate-stage disease (Barcelona Clinic Liver Cancer stage B), interest in combining transarterial chemoembolization and sorafenib has been reignited as a consequence of the TACTICS trial. In advanced-stage disease (BCLC C), external-beam radiotherapy combined with transarterial chemoembolization proved to be superior to sorafenib in patients with portal vein thrombosis according to the START trial. Also, in patients with advanced-stage HCC, the CELESTIAL trial demonstrated survival benefits for patients undergoing treatment with cabozantinib in the second-line setting. Lastly, recent data on the activity of pembrolizumab in patients with HCC highlight the role of immunotherapy in the management of this disease in the years to come. Dove Medical Press 2018-10-03 /pmc/articles/PMC6174912/ /pubmed/30324097 http://dx.doi.org/10.2147/JHC.S171396 Text en © 2018 de Jesus and Dettino. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
de Jesus, Victor Hugo Fonseca
Dettino, Aldo Lourenço Abbade
Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI)
title Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI)
title_full Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI)
title_fullStr Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI)
title_full_unstemmed Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI)
title_short Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI)
title_sort update on hepatocellular carcinoma from the 2018 gastrointestinal cancer symposium (asco gi)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174912/
https://www.ncbi.nlm.nih.gov/pubmed/30324097
http://dx.doi.org/10.2147/JHC.S171396
work_keys_str_mv AT dejesusvictorhugofonseca updateonhepatocellularcarcinomafromthe2018gastrointestinalcancersymposiumascogi
AT dettinoaldolourencoabbade updateonhepatocellularcarcinomafromthe2018gastrointestinalcancersymposiumascogi